"It is an honor to welcome two additional life science industry leaders to the BHI Board of Directors," said BioHealth Innovation's President & CEO Richard Bendis. "Dan brings a unique perspective from his role at the helm of one of the leading specialty pharmaceutical companies while Jens will provide important insight as the head of the corporate venture capital arm of GlaxoSmithKline (GSK). I'm also incredibly pleased that GSK, after having acquired Human Genome Sciences (one of the original investors in BHI), will continue to support BHI and has expressed an understanding of the importance of the mission of our organization." About Daniel J. Abdun-Nabi Mr. Abdun-Nabi is the president and chief executive officer of Emergent BioSolutions, positions he has held since March 2007 and April 2012, respectively. He has also served as a board member since May 2009. Mr.